<DOC>
	<DOCNO>NCT01740154</DOCNO>
	<brief_summary>The purpose research study determine sunitinib ( sunitinib malate ) cause fatigue . Patients ask complete brief questionnaire ( survey ) rate level fatigue every two week participate research study . The questionnaire take approximately 10-15 minute complete 9 question . A series physical measurement fatigue perform first dose sunitinib ( 4 ) week later see change physical level fatigue</brief_summary>
	<brief_title>Sunitinib Malate Related Fatigue Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine mechanism associate sunitinib relate fatigue record EMG signal submaximal elbow contraction , twitch force TMS prior end 4 week sunitinib metastatic RCC patient . OUTLINE : Patients receive sunitinib malate orally ( PO ) daily 4 week . Patients undergo neuromuscular test baseline day 28 complete fatigue assessment baseline day 14 28 .</detailed_description>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically proven renal cell cancer metastases ; pathology either primary metastatic tumor ; histologic subtype restriction Evidence measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) criteria version 1.1 evaluable disease Eastern Cooperative Oncology Group ( ECOG ) performance score 0 1 Hemoglobin &gt; = 9 gram/dL Common Terminology Criteria Adverse Events ( CTCAE ) fatigue level pretreatment &lt; 2 Signed date informed consent Greater 2 previous systemic treatment RCC Heart failure , New York Heart Association ( NYHA ) class 3 4 Unstable angina ( defined ongoing use nitrate cardiac ischemia prior 6 month ) Arrhythmia uncontrolled medication Hypertension ( &gt; 160/90 mmHg ) control medical management Brain metastases previous cranial radiation , leptomeningeal cancer Surgery within 2 week study entrance History stroke , myasthenia gravis , multiple sclerosis , polyneuropathy Pregnancy breast feed Centralnervous system active medication , intake withdrawal lower seizure threshold ( determination make consultation study 's responsible treat physician ) Any history epilepsy , convulsion seizure Medicationresistant epilepsy firstdegree relative Cochlear implant internal pulse generator cardiac pacemaker intracardiac line Metallic implant vicinity discharge coil head cervical spine Unexplained faint spells/syncope multiple concussion History severe head trauma ( followed loss consciousness ) Implanted brain spinal cord electrodes/stimulation Medication infusion device Frequent/severe headaches severe migraine Past current medical history diagnose undiagnosed tinnitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>